Tanya Gupta, MD

Following discussions on ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki, Tanya Gupta, MD, discusses sacituzumab govitecan and its approval from the FDA in the breast cancer space.

Tanya Gupta, MD, evaluates fam-trastuzumab deruxtecan-nxki and its role in breast cancer treatment.

Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast cancer.

Tanya Gupta, MD, discusses the current landscape of antibody-drug conjugates for breast cancer subtypes beyond HER2-positive disease.